PER 5.00% 10.5¢ percheron therapeutics limited

Ann: ATL1102 DMD Clinical Trial Application Submitted in Europe, page-21

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 13,363 Posts.
    lightbulb Created with Sketch. 1436
    Hi Mac9

    This from Morgan’s;

    Investment view▪ We continue to view ANP as one of the best risk / reward plays in the space and while short-term market risks have increased, the long-term rewards remain unchanged at this stage. Speculative Buy retained.▪ We remain buyers on further weakness for long-term
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.